Literature DB >> 31268471

Surrogate End Points and Patient-Reported Outcomes for Novel Oncology Drugs Approved Between 2011 and 2017.

Marjorie Zettler1, Ethan Basch2, Chadi Nabhan3.   

Abstract

Entities:  

Year:  2019        PMID： 31268471      PMCID： PMC6613294          DOI： 10.1001/jamaoncol.2019.1760

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  3 in total

1.  Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration.

Authors:  Talal Hilal; Miguel Gonzalez-Velez; Vinay Prasad
Journal:  JAMA Intern Med       Date:  2020-08-01       Impact factor: 21.873

2.  Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials.

Authors:  Bruce A Feinberg; Marjorie E Zettler; Andrew J Klink; Choo H Lee; Ajeet Gajra; Jonathan K Kish
Journal:  JAMA Netw Open       Date:  2021-02-01

3.  Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials.

Authors:  Zachary W Veitch; Daniel Shepshelovich; Christina Gallagher; Lisa Wang; Albiruni R Abdul Razak; Anna Spreafico; Philippe L Bedard; Lillian L Siu; Lori Minasian; Aaron R Hansen
Journal:  J Natl Cancer Inst       Date:  2021-08-02       Impact factor: 13.506
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.